Compression-grade tepoxalin is incorporated into rapidly disintegrating veterinary tablet cores at active loadings between 10% w/w and 25% w/w, with the remainder composed of microcrystalline cellulose, crospovidone at 2%–5% w/w, and magnesium stearate at 0.5%–1.0% w/w. The labeled canine dose schedule in some jurisdictions—20 mg/kg initial dose followed by 10 mg/kg once daily—translates into commercial tablet strengths of 50 mg, 100 mg, and 200 mg, which places content uniformity at the center of production control because the low-dose 50 mg core requires homogeneous distribution of a poorly compactible API. Direct compression is typically limited to batches where the API particle size d90 is below 30 µm and the blend flow satisfies a Carr index below 25% when assessed by USP <1174>; when compact tensile strength falls below 1.5 MPa, wet granulation with a povidone binder solution at 3%–7% w/w solids is introduced. The production-scale dry route uses a V-blender operated at 60% fill volume and 25 rpm for 15 min after geometric dilution of a 5 kg API pre-mix through a 500 µm stainless steel screen; blend uniformity testing per Ph. Eur. 2.9.6 and USP <905> requires 10 stratified sampling points with an acceptance value not exceeding 15. Tableting on a 16-station rotary press with B-tooling applies a pre-compression force of 2–4 kN and main compression force of 8–16 kN to produce cores with crushing strength between 40 N and 80 N; friability loss must not exceed 1.0% when tested according to Ph. Eur. 2.9.7, while disintegration time is controlled to 15 min or less in 37 °C purified water under Ph. Eur. 2.9.1. Dissolution is evaluated in 900 mL phosphate buffer at pH 6.8 using Apparatus 2 paddle speed 50 rpm, with Q not less than 80% at 30 min; however, because tepoxalin is weakly acidic and poorly soluble in gastric pH, dissolution failure at pH 1.2 may occur if the API particle size is increased above d90 50 µm, particularly in cores with hydrophobic fillers. The terminal finished products are immediate-release veterinary tablets for oral administration to dogs, packaged in PVC/aluminum blisters with desiccant, and the primary stability specification is VICH GL1 storage at 40 °C ± 2 °C/75% RH ± 5% RH for 6 months in the accelerated condition. The manufacturing authorization for these tablets must reference EU GMP Chapter 5 and VICH GL1 validation requirements; a batch release decision cannot be made unless the active assay is within 90.0%–110.0% of label, individual related substances are below 0.5%, and total impurities are below 2.0%.

What Limits Aseptic Filtration Throughput in Tepoxalin Injection Formulations?

Parenteral tepoxalin manufacturing is constrained by the low aqueous solubility of the free acid at pH values below 6.0; solution formulations therefore rely on co-solvent systems containing propylene glycol at 20%–40% v/v, ethanol at 5%–15% v/v, and tromethamine or sodium hydroxide for pH adjustment to 8.0–9.0. The API concentration is typically targeted between 10 mg/mL and 20 mg/mL, with benzyl alcohol at 1.0%–2.0% v/v as a preservative in multi-dose vials. A conflict arises between filtration throughput and pH-dependent hydrolysis: raising pH above 9.0 increases solubility but accelerates base-catalysed degradation when the solution is exposed to temperatures above 60 °C during terminal sterilisation trials. Published data for this specific configuration is limited; therefore, aseptic processing is the default route. The solution is blanketed with nitrogen to maintain dissolved oxygen below 0.5 mg/L and filtered through a 0.22 µm PVDF capsule at a differential pressure not exceeding 1.0 bar. Sterile filtration is performed in an isolator meeting EU GMP Annex 1 grade A conditions, and the filling line is validated for fill volume accuracy under USP <698>. Sterility testing follows Ph. Eur. 2.6.1 and bacterial endotoxins are tested per Ph. Eur. 2.6.14; the limit is calculated from the maximum dose delivered per kilogram body mass using K = 5 EU/kg, and for multi-dose vials a limit not exceeding 0.5 EU/mL is commonly applied. The finished injectable product is intended for perioperative or acute musculoskeletal pain management in companion animals under veterinary authorization, packaged in amber Type I glass vials sealed with butyl rubber stoppers. The critical operational boundaries include avoiding contact with strong oxidising acids, transition metal ions, and polyvinyl chloride containers due to sorption of ethanol and benzyl alcohol; filtration membrane compatibility must be validated because polyethersulfone may reduce preservative concentration below the 1.0% v/v specification.

Granule Matrix Engineering for Individualized Oral Powder Dosing

Granulated tepoxalin formulations are prepared for non-food companion animals requiring dose titration below the smallest tablet strength. The API addition ratio is generally limited to 1%–10% w/w because the free-flowing granule matrix must allow accurate splitting by measuring spoon or unit-dose sachet at strengths from 10 mg to 200 mg. Wet high-shear granulation is the selected process when the API is micronized and cohesive; the wet mass is produced in a 10 L high-shear mixer-granulator with impeller speed 250–350 rpm and chopper speed 1500–2500 rpm, using a binder solution of povidone K30 at 3%–5% w/w dry equivalent. The granules are dried in a fluid-bed dryer at inlet air temperature 55–65 °C until loss on drying is below 2.0%, then sieved through an oscillating granulator fitted with a 1000 µm mesh; oversize fraction above 1000 µm and fines below 150 µm are reworked at a ratio not exceeding 15% of fresh batch size to avoid dissolution variability. Compliance testing for particle size distribution uses analytical sieving per Ph. Eur. 2.9.12, and the release specification controls the d50 between 250 µm and 600 µm with uniformity of mass of single-dose sachets per Ph. Eur. 2.9.5. Dissolution from the granules is assessed with Ph. Eur. 2.9.3 Apparatus II at 50 rpm in 900 mL of pH 6.8 buffer; Q not less than 75% at 45 min is recommended for immediate-release granules. The finished powder or granule is filled into low-permeability sachets or polypropylene containers with child-resistant closures, and is intended for sprinkling on food or direct oral administration to dogs. A major limitation is that the medicated meal must be consumed immediately; due to interactions with fats and acidic food matrices, prolonged contact with wet pet food above 30 min can shift local pH and reduce recovery to below the labeled dose.

In hospitalized companion animal practice, hard-shell capsule manufacture for tepoxalin is selected when dose escalation protocols or clinical trial supplies require encapsulation of a granulated intermediate without the compression forces that can alter the API surface. The capsule fill contains tepoxalin at 5%–20% w/w, blended with lactose monohydrate size-controlled to d50 75–125 µm, and sodium starch glycolate at 2%–4% w/w to ensure capsule disintegration within 10 min under Ph. Eur. 2.9.1. The lubricant level is restricted to 0.5% w/w magnesium stearate, blended for 5 min after the main 15–20 min blend to avoid over-lubrication that could decrease dissolution through hydrophobic film formation on the API surface. Powder-in-capsule filling on a tamping-pin machine with 5 stations operates at a target capsule weight of 250 mg ± 5% for a 50 mg capsule; automatic checkweighing rejects units outside ±5% of target. Compliance testing requires content uniformity per USP <905> and dissolution using USP Apparatus 1 at 100 rpm in 900 mL of phosphate buffer pH 6.8, with Q not less than 80% at 30 min. The finished capsule product is used as a hospital-dispensed oral dosage form in companion animal medicine, particularly where tablet splitting would create dust exposure and inaccurate dosing in animals below 15 kg. The primary operational boundary is hygroscopicity: the gelatin shell becomes brittle below 40% RH and softens above 70% RH; before encapsulation, the granulated material should be dried to LOD below 1.5% and the encapsulation suite maintained at 40–55% RH and 20–25 °C. Chemical incompatibilities should be screened before registration batches because high-moisture disintegrants can cause localized swelling and capsule shell cracking; a pre-formulation compatibility screen under VICH GL1 accelerated conditions is therefore performed.

When Premix Formats Are Confined to Non-Food Species by Residue Rules

Medicated premix production using tepoxalin is governed less by mixing technology than by residue legislation that prohibits food-producing species use in the European Union because no maximum residue limit appears in Commission Regulation (EU) No 37/2010. Consequently, commercial premix formulations are limited to non-food companion animals—such as dogs in breeding establishments, shelters, or research colonies—where a uniformly distributed in-feed dose can support daily administration. The active substance is incorporated into a low-dust carrier premix at a concentration of 1%–10% w/w, with corncob meal or microcrystalline cellulose as carrier, and a vegetable oil binder at 0.5%–2.0% w/w to reduce segregation; butylated hydroxytoluene at 0.01%–0.05% w/w may be included where oxidative stability data justify it. Mixing is performed in a double-cone blender or ribbon mixer operated at 20 rpm for 10–15 min, with geometric dilution of the API under EU GMP Chapter 5 and sampling from 10 locations to demonstrate relative standard deviation of assay values below 5%. Homogeneity testing follows Ph. Eur. 2.9.40 for uniformity of content, and the sieving profile is controlled by Ph. Eur. 2.9.12 with d50 between 300 µm and 800 µm to reduce sifting in the final feed. The terminal finished product is a dry premix for addition to non-medicated feed at a rate calculated to deliver 10 mg/kg body weight; however, palatability deficits at inclusion rates above 2% w/w in the feed can reduce consumption in unsupervised colony settings, and direct admixture with high-fat feed pellets is not recommended because lipid extraction can transfer the API to the pellet surface and alter the consumed dose. In territories outside the EU, an export technical file must confirm the authorization status of tepoxalin for the target species; otherwise the premix is not legally marketable.

For precise low-volume titration in small companion animals, oral solution dosage forms of tepoxalin are manufactured as non-aqueous or co-solvent systems where tablet fractions cannot achieve the required 0.5 mg/kg dose increments. The target API concentration is commonly 10–25 mg/mL, dissolved in a vehicle composed of propylene glycol 30–50% v/v, glycerin 10–20% v/v, ethanol 5–10% v/v, and phosphate buffer pH 7.5–8.5 to maintain solubility without reaching the instability threshold above pH 9.0. Sodium metabisulphite at 0.05%–0.1% w/w may be added as an antioxidant in aqueous-containing formulations, and sucralose at 0.1%–0.3% w/w is used as a palatability agent for veterinary administration. The compounding sequence begins with dispersing the tepoxalin powder in propylene glycol and ethanol under a nitrogen blanket in a stainless steel jacketed vessel at 25–30 °C; the buffered aqueous phase is then added under low-shear mixing at 150–300 rpm to avoid local pH gradients. The solution is clarified through a 5 µm polypropylene depth filter, then filled into amber Type III glass or high-density polyethylene bottles with child-resistant closures; filling accuracy is verified by weight check under USP <698>. The finished oral solution is intended for direct administration by syringe or mixing with small volumes of food in dogs; the product should not be mixed with acidic fruit juices or carbonated drinks because a rapid drop below pH 6.0 can precipitate the free acid and reduce bioavailability. Compliance testing includes chemical assay by validated HPLC at release, related substances by Ph. Eur. 2.2.29, residual solvents per VICH GL18 for ethanol and propylene glycol, microbial examination of non-sterile products per Ph. Eur. 5.1.4, and stability under VICH GL1 conditions; the demonstrated use period after first opening should be limited to 30 days when water is present because of the risk of mold growth and ester hydrolysis in co-solvent systems.